Overview: JC Virus TestIntroduction: The JC Virus Test detects JC virus to diagnose progressive multifocal leukoencephalopathy (PML), causing neurological decline in immunocompromised patients, aiding in diagnosis. Affecting 1 in 100,000 immunocompromised individuals, PML poses diagnostic challenges due to rare occurrence. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses PCR for high sensitivity, supporting virology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: JC Virus Detection Test, PML Assay.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic reliability.
Historical Milestone: JC virus testing began in the 1990s with research by Major, who identified its role in PML. PCR advancements in the 2000s by Roche improved detection, surpassing earlier serology methods.
Purpose: Detects JC virus presence to diagnose PML, guides supportive care, and evaluates patients with neurological decline, aiming to manage disease.
Test Parameters: JC virus presence
Pretest Condition: No special preparation required. Collect CSF, urine, or whole blood. Report history of immunosuppression.
Specimen: CSF (sterile container, 1-2 mL), Urine (sterile container, 5-20 mL), Whole Blood (EDTA, 3-5 mL); 1 mL CSF or 2 mL serum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological decline or immunosuppression. Include current medications or HIV status.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., brain damage), and sample collection risks.
Procedural Considerations: Uses PCR to detect virus, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive result confirms PML, guiding care. Early management might slow progression, while untreated cases lead to death. Negative results may require MRI.
Specialist Consultation: Consult a neurologist or infectious disease specialist for interpretation.
Additional Supporting Tests: MRI, JC virus PCR, or immune status to confirm diagnosis.
Test Limitations: Specific to JC virus; correlation with imaging needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Neurovirology, Major EO, 2022.
